Monica Fabbrini

Molecular Basis of Branched Peptides Resistance to Enzyme Proteolysis

We found that synthetic peptides in the form of dendrimers become resistant to proteolysis. To determine the molecular basis of this resistance, different bioactive peptides were synthesized in monomeric, two‐branched and tetra‐branched form and incubated with human plasma and serum. Proteolytic resistance of branched multimeric sequences was compared to that of the same peptides synthesized as multimeric linear molecules. Unmodified peptides and cleaved sequences were detected by high pressure liquid chromatography and mass spectrometry. An increase in peptide copies did not increase peptide resistance in linear multimeric sequences, whereas multimericity progressively enhanced proteolytic stability of branched multimeric peptides. A structure‐based hypothesis of branched peptide resistance to proteolysis by metallopeptidases is presented.

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.

The irregular vasculature and high interstitial pressure of solid tumors hinder the delivery of cytotoxic agents to cancer cells. As a consequence, the doses of chemotherapy necessary to achieve complete tumor eradication are associated with unacceptably high toxicities. The selective thrombosis of tumor blood vessels has been postulated as an alternative avenue for combating cancer, depriving tumors of nutrients and oxygen and causing an avalanche of tumor cell deaths. The human antibody L19, specific to the EDB domain of fibronectin, a marker of angiogenesis, is capable of selective in vivo localization around tumor blood vessels and is thus a suitable agent for delivering toxic payloads to the tumor neovasculature. Here we show that a chemical conjugate of the L19 antibody with the photosensitizer bis(triethanolamine)Sn(IV) chlorin e6, after intravenous injection and irradiation with red light, caused an arrest of tumor growth in mice with subcutaneous tumors. By contrast, a photosensitizer conjugate obtained with an antibody of identical pharmacokinetic properties but irrelevant specificity did not exhibit a significant therapeutic effect. These results confirm that vascular targeting strategies, aimed at the selective occlusion/disruption of tumor blood vessels, have a significant anticancer therapeutic potential and encourage the use of antibody‐photosensitizer conjugates for the therapy of superficial tumors and possibly other angiogenesis‐related pathologies.

Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting

Receptors for endogenous regulatory peptides, like the neuropeptide neurotensin, are overexpressed in several human cancers and can be targets for peptide-mediated tumor-selective therapy. Peptides, however, have the main drawback of an extremely short half-life in vivo. We showed that neurotensin and other endogenous peptides, when synthesized as dendrimers, retain biological activity and become resistant to proteolysis. Here, we synthesized the neurotensin functional fragment NT(8-13) in a tetrabranched form linked to different units for tumor therapy or diagnosis. Fluorescent molecules were used to monitor receptor binding and internalization in HT29 human adenocarcinoma cells and receptor binding in HT29 tumor xenografts in nude mice. Linking of chemotherapic molecules like chlorin e6 and methotrexate to dendrimers resulted in a dramatic increase in drug selectivity, uptake of which by target cells became dependent on peptide receptor binding. When nude mice carrying human tumor xenografts were treated with branched NT(8-13)-methotrexate, a 60% reduction in tumor growth was observed with respect to mice treated with the free drug. [Mol Cancer Ther 2007;6(9):2441–8]

Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo

The lethal and oedema toxins produced by Bacillus anthracis, the aetiological agent of anthrax, are made by association of protective antigen with lethal and oedema factors and play a major role in the pathogenesis of anthrax. In the present paper, we describe the production of peptide-based specific inhibitors in branched form which inhibit the interaction of protective antigen with lethal and oedema factors and neutralize anthrax toxins in vitro and in vivo. Anti-protective antigen peptides were selected from a phage library by competitive panning with lethal factor. Selected 12-mer peptides were synthesized in tetra-branched form and were systematically modified to obtain peptides with higher affinity and inhibitory efficiency.

Solubility improvement of an anthrax toxin peptide inhibitor by rational aminoacid randomization

We previously described a potent anthrax toxin inhibitor, based on a phage-library-selected peptide sequence, synthesized as a tetra-branched molecule on a lysine core and further modified for improvement of activity [Pini et al., Biochem. J., 2006, 395, 157]. This branched peptide had very low solubility because of several hydrophobic residues in the peptide sequence. This complicated molecule purification and manufacturing. Here we report a rational modification of the peptide sequence, obtained by construction and selection of several mini libraries of branched peptides, containing sequences randomized in non crucial positions of the original peptide. Mini libraries were screened for solubility and inhibitory activity. This procedure enabled us to obtain a new peptide with a better solubility and identical inhibitory activity.

Branched Neurotensin for Tumor Targeting

Introduction One of the major problems in classic chemotherapy is the non-specific toxicity of most anticancer agents against normal cells. The specific targeting of tumors has been the main challenge in research on cancer therapy and diagnosis. Presently, innovative tumor-specific therapies address tumor cells via tumor associated antigens, specifically expressed or over expressed on tumor cells, and deliver cytotoxic moieties directly producing tumor cell death. The observation that receptors for different endogenous regulatory peptides are expressed in a number of primary human cancers opened new perspectives on the use of synthetic peptides for tumor-selective targeting [1]. In fact, anticancer drugs or radiotracers have been coupled to analogs of many regulatory peptides. Nonetheless, the use of peptides in vivo has largely been limited by their short half-life. In a previous study we reported that the synthesis of bioactive peptides in dendrimeric MAP form can result in increased half-life, due to acquired resistance to protease and peptidase activity [2]. Our results indicated that synthesis in dendrimeric form may be a general method to increase in vivo stability of bioactive peptides. Currently, analogs of neurotensin (NT) and particularly of its short active fragment NT(8-13) are under investigation to target a variety of neuroendocrine human tumors (prostate, pancreatic, and small cell lung cancer) over-expressing NT receptors [1,3]. Nonetheless, chemical modifications of NT sequence aimed to increase its half-life, significantly decrease peptide receptor affinity. We demonstrated that the binding activity of branched NT and NT(8-13) is fully retained or enhanced. Moreover tetrabranched peptides become much more resistant to proteolysis. These results bring new perspectives to the use of NT as a carrier for tumor targeting tracers or therapeutics.